For research use only.
Licensed by Pfizer Catalog No.S1808
CAS No. 21829-25-4
Nifedipine (BAY-a-1040) is a dihydropyridine calcium channel blocker, used to lower hypertension and to treat angina.
Selleck's Nifedipine (BAY-a-1040) has been cited by 11 publications
2 Customer Reviews
The fold change of C-peptide content after octreotide, nicorandil and nifedipine treatment. Octreotide, nicorandil and nifedipine decreased insulin secretion in wild-type, heterozygous mutated and homozygous mutated cells.
Sci Rep, 2017, 7(1):3156. Nifedipine (BAY-a-1040) purchased from Selleck.
INS-1 cells and MIN6 cells were treated by 40 mM KCl alone or combination with 10 μM nifedipine and Bay K 8664 for 1 h and then the SAD-A expression was detected by western blotting. * indicates a non-specific band.
Biochem Biophys Res Commun, 2019, 509(1):76-81. Nifedipine (BAY-a-1040) purchased from Selleck.
Purity & Quality Control
Choose Selective Calcium Channel Inhibitors
|Description||Nifedipine (BAY-a-1040) is a dihydropyridine calcium channel blocker, used to lower hypertension and to treat angina.|
Nifedipine causes a significant concentration-dependent increase in eNOS protein expression by cultured human coronary artery endothelial cells.  Nifedipine antagonizes L-type Ca+ channels found throughout the cardiovascular system, but also blocks Kv channels, which are members of the same supergene family.  Nifedipine dose-dependently decreases the values of [(3)H]-thymidine incorporation and total cellular protein content as well as the levels of phosphorylated extracellular signal-regulated protein kinase (ERK) 1/2, mitogen-activated protein kinase kinase (MEK) 1/2, and even the phosphorylation of Pyk2, in vascular smooth muscle cells (VSMC). Nifedipine suppresses the levels of proliferative cell nuclear antigen (PCNA) dose-dependently in both VSMC and balloon-injured thoracic aortae in VSMC. 
|In vivo||Nifedipine (3 mg/kg) slightly lowers the level of systolic and/or diastolic blood pressure or increased the heart rate in rats.  Nifedipine (1 μm) produces a maximal inhibition of the store-operated pathway in choroidal arteriolar smooth muscle.  Nifedipine (20 and 40 mg/kg) markedly prevents the HCl plus ethanol-induced gastric mucosal injury and the increase in the content of thiobarbituric acid-reactive substances in the injured mucosa in rats. Nifedipine (20 and 40 mg/kg) dose-dependently promotes the ulcer healing and inhibites the increase in the content of thiobarbituric acid-reactive substances in the ulcerated mucosa in rats. |
-  Ding Y, et al. J Pharmacol Exp Ther,?000, 292(2), 606-609.
-  Zhang X, et al. J Pharmacol Exp Ther,?997, 281(3), 1247-1256.
-  Hirata A, et al. Br J Pharmacol,?000, 131(8), 1521-1530.
|In vitro||DMSO||69 mg/mL (199.23 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Storage||2 years 4°C(in the dark) powder
1 week 4°C(in the dark) in solvent
In vivo Formulation Calculator (Clear solution)
|Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)|
|Dosage||mg/kg||Average weight of animals||g||Dosing volume per animal||ul||Number of animals|
|Step 2: Enter the in vivo formulation ()|
|% DMSO % % Tween 80 % ddH2O|
Working concentration： mg/ml；
Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL，)
Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH2O，mix and clarify.
1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT04392375||Recruiting||Drug: Nifedipine 30 MG|Drug: Placebos||Preeclampsia Severe||Ohio State University||June 9 2020||Phase 4|
|NCT02902354||Withdrawn||Other: Nifedipine for tocolysis||Tocolysis With Nifedipine||St. Louis University||September 2016||Not Applicable|
|NCT03710395||Unknown status||Procedure: Blood and breast milk sampling|Drug: Nifedipine||Drug Transporter||Natalia Valadares de Moraes|Hospital das Clínicas de Ribeirão Preto|Universidade Estadual Paulista Júlio de Mesquita Filho||December 14 2015||Phase 4|
|NCT02068404||Unknown status||Drug: Nifedipine||Preterm Labor||Chantal Csajka|Centre Hospitalier Universitaire Vaudois||April 2014||Phase 4|
|NCT02023047||Terminated||Drug: Nifedipine 12 mg coated suppositories||Anal Fissure||RDD Pharma Ltd||March 2014||Phase 1|Phase 2|
|NCT01021501||Unknown status||Drug: nifedipine controlled release tablets||Hypertension on Chronic Maintenance Hemodialysis||Guangzhou First People''s Hospital||December 2009||Phase 4|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.